Istituto Giannina Gaslini

Running trials

• Not yet recruiting

  An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program.

  2026-525677-39-00· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

  NCT07858123· Phase 3· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Source

• Recruiting

  Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis

  NCT07809867· Phase 4· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

  NCT07587242· Phase 3· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

  2025-523087-20-00· Phase 3· Source

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· Source

• Active, not recruiting

  A study to learn about how well BAY 3401016 works in adults with Alport syndrome

  2024-516471-33-00· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  NCT07227454· Phase 3· Source

• Recruiting

  Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma

  2024-518167-35-01· Phase 2· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Source

• Recruiting

  A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07188805· Phase 3· Source

• Recruiting

  Study of Ravulizumab in Pediatric Participants With Primary IgAN

  NCT07024563· Phase 3· Source

• Recruiting

  An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

  NCT05066217· Phase 3· Source

• Recruiting

  Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

  NCT06485947· Phase 1· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· Source

• Active, not recruiting

  A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

  NCT06413706· Phase 2· Source

• Active, not recruiting

  LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

  NCT02205762· Phase 2/3· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

  NCT06392009· Phase 1/2· Source

• Recruiting

  A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

  NCT06392386· Phase 2/3· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Source

• Recruiting

  Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia

  NCT06166706· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma

  2022-502984-39-00· Phase 3· Source

• Recruiting

  TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neuroblastoma

  2024-519089-32-02· Phase 2· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Source

• Active, not recruiting

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· Source

• Recruiting

  Asciminib Roll-over Study

  NCT04877522· Phase 4· Source

• Enrolling by invitation

  Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

  NCT05374590· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

  NCT05039619· Phase 2· Source

• Recruiting

  Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

  NCT05156398· Phase 3· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Source

• Recruiting

  High Dose Steroids in Children With Stroke

  NCT04873583· Phase 3· Source

• Recruiting

  SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

  2024-510578-25-00· Phase 3· Source

• Active, not recruiting

  Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

  NCT04833894· Phase 2/3· Source

• Recruiting

  Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

  NCT05003986· Phase 2· Source

• Recruiting

  Observational Study in Localized Osteosarcoma

  NCT04890067· Source

• Recruiting

  A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

  NCT04965675· Phase 3· Source

• Recruiting

  Observational Study on Skeletal Ewing's Sarcoma

  NCT04845893· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Recruiting

  Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

  NCT04793919· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers21 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Neuroblastoma4 recruiting
• Sarcoma4 recruiting
• Duchenne muscular dystrophy3 recruiting
• IgA nephropathy3 recruiting
• Myasthenia gravis3 recruiting
• Epilepsy2 recruiting
• Haemophilia2 recruiting
• Heart failure2 recruiting
• Acute myeloid leukemia1 recruiting
• Asthma1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Lupus (SLE)1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Source

• Completed

  A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis

  2023-504092-25-00· Phase 2· Source

• Completed

  Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

  NCT05794139· Phase 2· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Source

• Completed

  Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

  NCT05322096· Phase 2· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Source

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Source

• Active, not recruiting

  Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  NCT04150497· Phase 1/2· Source

• Withdrawn

  Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

  NCT03349346· Phase 1· Source

• Completed

  Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

  NCT02913482· Phase 2· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Source

• Completed

  Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

  NCT02369731· Source

• Completed

  ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

  NCT01459484· Phase 2· Source

Trial sites

• IRCCS Istituto Giannina Gaslini67 trials
• IRCCS Istituto Giannina Gaslini - Cardiologia0 trials
• IRCCS Istituto Giannina Gaslini /ID# 2552620 trials
• IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene0 trials
• IRCCS Istituto Giannina Gaslini (Site 1603)0 trials
• IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative1 trial
• Istituto Giannina Gaslini0 trials
• Istituto Giannina Gaslini IRCCS0 trials
• Istituto Giannina Gaslini9 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Epilepsy73 works · 4 trials
• Neuroblastoma48 works · 6 trials
• Childhood cancers29 works · 33 trials
• Cystic fibrosis25 works · 4 trials
• Spinal muscular atrophy12 works · 3 trials
• Duchenne muscular dystrophy9 works · 6 trials